INTRODUCTION
Cataract is a major cause of visual loss in patients with uveitis; up to 40% of the visual loss is either solely or largely due to cataract. 1 Surgical treatment may be effective, but is associated with higher complication rates than that in eyes without previous uveitis. Quantifying this risk is important in order to inform patients and surgeons as to the likely short-term and long-term benefits or harm of undertaking cataract surgery, and may affect the timing of such surgery.
Currently, most data on cataract surgery in patients with uveitis come from small case series or cohort studies, with data gathered over long time periods to attain sufficient numbers. As this may be so long that practice changes, the studies may not reflect current practice, or be generalisable. [2] [3] [4] [5] [6] [7] The outcome of cataract surgery in patients with uveitis is regarded as far less predictable than in most groups of patients, due to numerous factors including technical challenges at the time of surgery, the uncertain impact of inflammatory sequelae and the variable and unpredictable reversibility of these complications.
The relative paucity of evidence on which to base treatment decisions was noted in a survey of uveitis practitioners by Sreekantam et al, 8 in which the majority stated that there was no or only lowlevel published evidence to support key treatment decisions regarding perioperative management and choice of intraocular lens (IOL) in these patients. There is a real need for large volume population data in patients with uveitis to help bridge this evidence gap, improving the decision-making process and helping inform patient and clinician expectations around outcome.
The use of electronic medical record (EMR) systems provides a way of acquiring large-scale prespecified standardised data that are relevant to daily practice. In the context of cataract surgery, we have recently reported on a multicentre database study of 81 984 eyes undergoing cataract surgery in the UK. 9 The UK National Health Service (NHS) is an ideal setting for this study, because it serves more than 90% of the population for cataract surgery, and there has been widespread adoption of EMR systems that mandate collection of detailed standardised datasets developed by The Royal College of Ophthalmologists. 10 11 The ability to pool anonymised data from multiple centres enables relatively precise estimates of complication rates even for uncommon conditions such as uveitis. It also means that there is sufficient power for hypothesis testing. This is particularly relevant to complex diseases, such as uveitis, for which multiple complications of the disease present at the time of surgery may affect visual outcome and would ideally be factored into any estimate of the risk of undertaking surgery.
The primary aim of this study is to define the estimates of the likelihood and magnitude of visual gain and the risk of intraoperative and postoperative complications in uveitic eyes undergoing cataract surgery in a real-world setting compared with eyes without uveitis.
MATERIALS AND METHODS
Eight independent NHS hospital ophthalmology departments in the UK using the same EMR system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK) provided routinely captured clinical data, based upon nationally standardised datasets approved by The Royal College of
Ophthalmologists. 10 Approval from the lead clinician and Caldicott Guardian was obtained for all sites before extraction of the anonymised data. The Declaration of Helsinki, UK Data Protection Act and National Institute for Health Research (NIHR) guidance on ethical approval were adhered to.
The study period was from 1 January 2010 to 31 December 2014. All sites performed small-incision day-case phacoemulsification surgery. Raw data were electronically extracted and anonymised in May 2015. No verification against paper records was made as part of this study; so, fidelity of documentation cannot be determined.
Following the decision to operate by an ophthalmologist, all sites recorded standardised nurse-led preoperative assessment (with multiple standard data fields mandated by the EMR) and biometry. Routine postoperative care included a single visit 4-6 weeks following surgery conducted by a specialist nurse or optometrist. Eyes identified as high risk, such as those with known uveitis, were more likely to be reviewed earlier by an ophthalmologist.
Data fields extracted on demographics and preoperative characteristics included: age, gender, laterality, visual acuity (VA), intraocular pressure, diabetic status and ETDRS grading if relevant, use of preoperative intravitreal steroid, use of preoperative topical non-steroidal anti-inflammatory drugs (NSAIDs) and the presence of glaucoma, trabeculectomy and other pre-existing copathologies and use of prostaglandin analogues.
Data fields extracted from intraoperative records included: pupil size, grade of operating surgeon, use of pupil manipulation, any intraoperative complications, capsular rupture with or without vitreous loss and combined procedures such as pars plana vitrectomy.
Data fields extracted from postoperative visits included: VA, intraocular pressure, use of intravitreal corticosteroid or topical NSAIDs, and whether there was any record of the development of cystoid macular oedema.
All eyes of patients who did not have their diabetic status recorded were excluded from subsequent analyses. The remaining eyes were classified as either uveitic or non-uveitic. Eyes were classified as uveitic if the term 'uveitis' was selected in the mandatory copathology field for the operated eye at the time of surgery, or if there was any recorded diagnosis including the word 'uveitis' or either of the two terms 'neuroretinitis' or 'ocular sarcoidosis' at any preoperative visits. The latter terms were included as pre-existing specific diagnoses available from the limited prepopulated diagnosis database not featuring the term 'uveitis'. In the EMR version used, more common specific diagnoses were not readily available.
Preoperative VA and intraocular pressure (IOP) used the values recorded closest to the date of surgery. If no value was recorded within 3 months prior to surgery, the eye was excluded from analysis. Postoperative VA and IOP used the last recorded measurements within each time period. If VA was recorded in Snellen fractions, these were converted to logarithm of the minimum angle of resolution (logMAR) units, with values corresponding to count fingers, hand movements, perception of light (PL) and no PL, substituted with 2.10, 2.40, 2.70 and 3.00 logMAR units, respectively. 10 Pre-existing copathologies were not mutually exclusive and were analysed individually, but the aggregate number of copathologies for each eye (single or multiple) was also presented.
Due to the anonymised extraction of records, it was not possible in this study to identify, which patient each eye belonged to, and therefore it was not possible to differentiate between two eyes from the same individual. Therefore, all eyes were treated as independent units for the purpose of data analysis.
Comparisons of multiple preoperative, intraoperative and postoperative characteristics and outcomes were made between eyes with uveitis (uveitic group) and those with no uveitis (reference group). To prevent the confounding effect of diabetic macular oedema on the occurrence of pseudophakic macular oedema, eyes of patients with diabetes were excluded from this particular analysis. Differences between groups were tested for statistical significance using multiple t-test analyses with the Holm-Šídák method for multiple comparisons or χ 2 tests for independence as indicated in figure legends using GraphPad Prism V.6.00 (GraphPad Software, La Jolla, California, USA). Linear regression was performed using STATA (StataCorp. 2013. Stata Statistical Software: Version 13. College Station, Texas, USA: StataCorp LP).
RESULTS
An initial dataset was collected on a total of 111 641 eyes comprising all eyes undergoing cataract surgery between January 2010 and December 2014 at eight centres. Of this cohort, 14 895 eyes were excluded, as the diabetic status was not recorded. Of the remaining eyes, 1173 eyes were classified into the uveitis group and 95 573 eyes were classified into the non-uveitis reference group. Tables 1 and 2 show the preoperative demographic and clinical characteristics of the eyes and patients. The uveitic group was associated with a younger age, worse VA and a higher prevalence of coexisting glaucoma, previous trabeculectomy, prior use of topical prostaglandin analogues, intravitreal corticosteroid administration, and possessing one or more coexisting pathologies, shorter axial length and less high myopia. The reference cohort was associated with a greater prevalence of type II diabetes and age-related macular degeneration. There was no statistically significant difference between the two groups in terms of gender, laterality, preoperative topical NSAID use, the presence of epiretinal membrane, amblyopia, corneal pathology, Tables 3 and 4 show the differences in intraoperative and postoperative characteristics between the two groups. The uveitic group was associated with smaller pupil size, having surgery performed by consultant surgeons, requiring surgical pupil manipulation, or combined surgery such as planned pars plana vitrectomy. A higher incidence of posterior capsule rupture was documented when only cases performed by senior surgeons were compared between the two groups. No correlation between VA gain and total surgeon or cataract numbers at different sites was seen (see online supplementary figure 1).
The uveitic group was associated with poorer VA at all three postoperative time points of 4 weeks, 4-12 weeks and 12-24 weeks, higher postoperative IOP and over twice as high preponderance of postoperative macular oedema (3.33% vs 1.35% p<0.0001), once eyes of patients with diabetes were excluded from the analysis. Eyes of patients with uveitis had a mean preoperative VA of 0.87 compared with 0.65 LogMAR units in controls. At 12-24 weeks postoperatively, mean VA was 0.41 and 0.27 LogMAR units, respectively. As a cohort, on average, both groups of eyes improved by three to four lines on the LogMAR chart. Using a multivariate regression model controlling for preoperative VA, the mean postoperative VA was significantly associated with uveitic status (coefficient 0.085; 95% CI This implies both improve proportionately to preoperative VA, although eyes with uveitis were on average 0.085 LogMAR worse postoperatively compared with controls.
Marked visual harm defined as a loss >0.3 logMAR units from preoperative baseline was assessed at 12-24 weeks postoperatively, where data were available. The incidence was 3.8% of eyes in the uveitic group (16 of 421 eyes); however, this was not statistically different from those in the control group at 2.9% (826 of 28 305, p=0.3577, χ 2 ). Eyes with uveitis suffering marked visual harm showed no consistent intraoperative complications, but had a higher mean IOP (21.3 vs 15.9 mm Hg) and greater incidence of glaucoma surgery (12.5% vs 1.2%).
DISCUSSION
This is the largest real-world study of cataract surgery in patients with uveitis reported, and provides clear evidence of the burden of disease, additional risk of complications and worse visual outcomes in this cohort. Based on the analysed 96 746 eyes from eight different centres, eyes with uveitis are noted to account for 1.2% of all cases and represent a younger, surgically demanding cohort, which may require significant additional resources at each treatment stage. Our study shows that while surgery for cataract in eyes with uveitis is associated with an improvement in mean VA, there are significantly higher rates of both intraoperative and postoperative complications with final VA in the uveitic cohort worse than the non-uveitic cohort at all time points.
Visual outcome
The key finding that cataract surgery is associated with improved visual outcome in patients with uveitis is consistent with previous studies. A systematic review analysed 13 studies of phacoemulsification, 10 of extracapsular cataract extraction and 8 of pars plana lensectomy in mixed groups of patients with uveitis. It noted overall 71% that had IOL implantation achieved 20/40 postoperatively vs 52% of those left aphakic. 12 The review however contains a high proportion of older studies (up to 1997 for phacoemulsification), and mixes prospective and retrospective designs. Our study showed that of 1173 uveitic eyes undergoing cataract surgery between 2010 and 2014, 69% achieved a VA of at least 20/40 in the 4-12 week postoperative interval. Given recent advances in surgical (IOL, phacoemulsification machine, surgical technique) and medical aspects (increased range of drugs to control uveitis including local therapies), it is salutary that visual outcomes observed are similar to the systematic review, suggesting that there has not been a significant improvement in outcome during the intervening period.
More recent studies are limited by their size (and in some cases design), but do provide a useful comparison, with similar outcomes to our study. A single-surgeon retrospective study in 171 uveitic eyes reported that at 6 months, a VA of 20/40 or better was achieved in 71% of eyes. 6 A small non-masked randomised controlled trial investigating the effect of perioperative oral corticosteroid in 52 uveitic eyes undergoing phacoemulsification reported a VA improvement from 0.68 to 0.31 logMAR in the standard therapy group (intensive topical corticosteroid) and from 0.75 to 0.20 in the intervention group (intensive topical plus oral corticosteroid). 13 During the 2-year follow-up of the Multicenter Uveitis Steroid Treatment Trial, 117 eyes underwent cataract surgery, where 62% of eyes achieved a VA of 6/12 or better at the 3-month postoperative visit, from a median of 56 letters at baseline to 79 letters at 3 months.
14 A multicentre trial randomising 126 uveitic eyes to phacoemulsification versus small incision cataract surgery noted that 44% achieved at least 20/36 and 91% achieved at least 20/63 at 6 months in the phacoemulsification group. 15 Our study provides a large survey of contemporary practice in an unselected uveitis cohort, where all data were gathered into prospectively fixed data fields, then analysed retrospectively. This has clear advantages over smaller retrospective studies in terms of scale, but also avoids the selection bias inherent in studies that arise from single tertiary centres. The eight centres included in our study comprise a wide range of settings and size, providing a good representation of the UK population.
Risk of surgery
This study confirms that the uveitic population differs in being younger, with more advanced cataract and having much higher rates of copathology. Many of these pathologies will limit visual outcome. Surgery is shown to be technically more challenging with small pupils recorded in nearly one-third of all uveitic eyes and significantly higher rates of additional procedures being required. The additional skill required is demonstrated by the larger proportion performed by consultant (senior) surgeons.
It is likely that the worse preoperative VA represents a combination of the presence of more advanced cataract in this cohort with higher rates of visually significant preoperative copathology, which is supported by the fact that mean VA fails to recover to the same levels as in the non-uveitic cohort. While over two-thirds of eyes operated upon gained VA of at least 20/40, the more guarded prognosis might mean surgeon and patient preference may delay the decision to operate or be enforced by difficulties in achieving inflammatory control. Our linear regression model indicates, despite uveitic status, preoperative VA is the key determinant of postoperative VA. This association suggests delaying until VA significantly deteriorates might not always be the preferred option.
Direct comparison with other studies is difficult due to the variation in reporting. However, where evidence is available, studies report a high rate of additional procedures, notably intraoperative iris hook use between 19% and 67%, but a low risk of intraoperative complications. 6 13 15 The largest of these studies reported no posterior capsular ruptures in any of 171 uveitic eyes undergoing surgery. 6 
Limitations
This study has a number of limitations. First, it is entirely observational. It allows the detection of interesting associations, estimates of risks and provides valuable benchmark data, but cannot provide high-level evidence to justify any particular intervention that a clinical trial might. Furthermore, EMR data could not be readily checked against paper medical notes; so, the exact degree of verification is uncertain.
Second, a number of datafields are non-compulsory, leading to higher rates of missing data than would be seen in a prospective clinical trial. Additionally, the accuracy of data entry is not subject to the routine audits of a trial. Our study does benefit from almost complete datasets for key variables of VA and presence of complications, which are compulsory fields mandated by the software. In contrast, some other variables which might be used to stratify patient risk are not compulsory, and thus are not available for analysis in our dataset. For example, details of the uveitic syndrome are not compulsory, and so we have not attempted subgroup analysis by uveitis anatomical subtype or syndrome. Previous studies suggest that the prognosis may vary across uveitis subtype, and this should be considered when counselling patients preoperatively. 12 14 The inclusion strategy means the eyes included were predominantly those where the surgeon selected the copathology 'uveitis' at the time of operation. With regard to the use of corticosteroids, immunosuppressants and other treatments, the EMR could only capture a limited range of data, which was not sufficient to undertake meaningful subgroup analysis or stratification.
Finally, we acknowledge that due to the 'real-world' setting of our study, the follow-up visits were not fixed. We dealt with this by grouping follow-up visits into prespecified intervals, reflecting clinically relevant follow-up periods. While not all patients had visits during all the three time frames reported, the scale of the study means that at any single time point, more than 400 uveitic eyes and 28 000 non-uveitic eyes were assessed. Indeed, in the 4-12 week time point, 595 uveitic eyes and 50 611 non-uveitic eyes were assessed, an unparalleled resource from a single study. 
